Novartis chief sees sales dip until mid-2013
Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.
Oct 7, 2012
0
0